My guess is that the market is not favorable for
secondary offerings. I have noticed in various press
releases that biotech companies are trying to be creative
when trying to raise capital.
The plus to this
scenario is that the interest which is owed can be
expensed every year even though it isn't paid until the
notes are due at some future time. So I guess this help
the bottom line (Profit figure).
shares would lower the earning per share figure if
everything stayed the same. But I think their drug is really
going to take off. I read an article that appeared in
the newly released issue of the Journal of
Oncology(January 99). They just completed a study using the IDEC
antibody in combination with chemotherapy. The got an
overall response rate of nearly 100%. 55% of the patients
experienced complete remissions while 40% experienced
experienced partial remissions. This is better than the
antibody therapy alone. Just wait until the Oncologist
start using this new treatment. It going to start
selling like water.
You mentioned an article in "Journal of
Oncology(January 99)". Is this the article you meant?
McLaughlin P, et al.
Clinical status and optimal use of
rituximab for B-cell lymphomas.
1998 Dec;12(12):1763-9; discussion 1769-77, 1781.
If not could you provide an author name and the
exact title and/or journal name, so I can find it? Much
I believe there is a lot of this going on the
clinicians' offices already - that is, using Rituxan with
standard chemotherapy. My oncologist told me that after a
regimen of CHOP for newly diagnosed NHL (a standard chemo
treatment), he and his group are "maintaining" their patients
on Rituxan. This is very similar to the trial
currently under way, whose good results you cited. His
group loves Rituxan and they're using it every which
way - never mind what the label says. I believe this
is what was alluded to in the Lehman report which
stated that they expect greater penetration of the
market, due to more off-label use, among other things.
Now, can anyone tell me when Rituxan gained FDA
approval and when it was first available to
I'm going somewhere with this, so please bear with
me. I'll fill you in later - as I gain more knowledge
about this drug and the company.
I saw on
Comapny Sleuth where IDECPHARM.COM was registered to IDPH
so I'm going out to the net to see is they have a
homepage where I can gather some of this information
In the meantime, thanks to those of you who
From the BobLLL archives...
First New Drug for Non-Hodgkin's Lymphoma in Decade
Receives FDA Clearance for Marketing
Monoclonal Antibody for Therapeutic Use in Cancer
DIEGO and SOUTH SAN FRANCISCO, Calif.--(BW
HealthWire)-- Nov. 26, 1997--IDEC Pharmaceuticals Corporation
(NASDAQ:IDPH - news) and Genentech, Inc. (NYSE:GNE - news)
today announced that RITUXAN(TM) (Rituximab) has been
cleared for marketing by the U.S. Food and Drug
Administration (FDA). Rituxan, previously know as the C2B8
antibody, is a single-agent monoclonal antibody therapy for
the treatment of relapsed or refractory low-grade or
follicular, CD20-positive B-cell non-Hodgkin's lymphoma.
. . .
It is expected to be commercially
available for use within approximately three weeks.
I don't remember if
this press release was on the exact day of FDA
approval, but very close. Actually the FDA essentially
approved it a couple months earlier, as to medical
criteria, but full approval was delayed until some
manufacturing issues were resolved to FDA approval.
bear in mind that most HMO and insurance companies
have their own procedures for deciding what they will
pay for. I check with my own very large HMO and was
told this process takes 3 to 6 months after FDA
approval. A persistant patient could bypass the procedure
and get it sooner, but they would have to be, well,
I mention all this as it affected early
sales numbers, since I don't know "where you are going
with this." Do let us know.
I don't think IDEC has a webpage. Considerable
info is available on the Genentech webpage,
particularly the "full prescribing information", aka the
"package insert" that comes with the product at the
Of course, that is medical information. Details on
chemistry, how it works (to the extent they know),
indications, warnings, adverse events, etc. What information
are you looking for?
IDEC Corporation manufactures products that
simplify interaction between humans and machines.
With a comprehensive line of products, from relays and
switches to sensors and micro PLCs, IDEC provides critical
solutions for industrial equipment manufacturers as well as
advanced technical applications.
international headquarters in Sunnyvale, California, IDEC has
served customers throughout the world for over 23 years.